|
注册号: Registration number: |
ChiCTR-TRC-12002026 |
|
最近更新日期: Date of Last Refreshed on: |
2015-08-04 21:29:17 |
|
注册时间: Date of Registration: |
2012-03-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
出血性脑卒中微创治疗技术多中心、随机对照试验 |
|
Public title: |
The Minimally Invasive Treatment Technique For the Hemorrhagic Stroke: A Multicenter, Randomized, Controlled Clinical Trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
出血性卒中病因学评价与微创治疗技术研究 |
|
Scientific title: |
Research on the Etiological Assessment and the Minimally Invasive Treatment Technique For the Hemorrhagic Stroke |
|
研究课题代号(代码): Study subject ID: |
2011BAI08B05 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李浩 |
研究负责人: |
游潮 |
|
Applicant: |
Hao Li |
Study leader: |
Chao You |
|
申请注册联系人电话: Applicant telephone: |
+86 13882279538 |
研究负责人电话:
Study leader's |
+86 18980601505 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
neurosurgery_lh@hotmail.com |
研究负责人电子邮件: Study leader's E-mail: |
youchao@tfol.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
四川省,成都市,国学巷37号,四川大学华西医院,神经外科 |
研究负责人通讯地址: |
四川省,成都市,国学巷37号,四川大学华西医院,神经外科 |
|
Applicant address: |
37 Guoxuexiang, Chengdu, Sichuan, China |
Study leader's address: |
37 Guoxuexiang, Chengdu, Sichuan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
610041 |
研究负责人邮政编码: Study leader's postcode: |
610041 |
|
申请人所在单位: |
四川大学华西医院 |
||
|
Applicant's institution: |
West China Hospital, Sichuan University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
106 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
四川大学华西医院临床试验与生物医学伦理专委会 |
||
|
Name of the ethic committee: |
Ethics Committee of Clinical Trials and Biomedical, West China Hospital, Sichuan University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2012-04-06 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
四川大学华西医院 |
||||||||||||||||||||||
|
Primary sponsor: |
West China Hospital, Sichuan University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
四川省,成都市,国学巷37号,四川大学华西医院,神经外科 |
||||||||||||||||||||||
|
Primary sponsor's address: |
37 Guoxuexiang, Chengdu, Sichuan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
“十二五”国家科技支撑计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
the National Key Technology R&D Program for the 12th Five-year Plan of P.R.China (No.2011BAI08B05). |
||||||||||||||||||||||
|
研究疾病: |
出血性卒中 |
||||||||||||||||||||||
|
Target disease: |
Hemorrhagic Stroke |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
IV期临床试验 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.建立以针电极颅内压、脑温及生物信息监测系统监控下的微创治疗系统。 2.针对高血压性脑出血,开发CT介导下的仿真脑结构及功能定位分析系统; 3.评价并规范CT立体定位下微创血肿清除术的确切疗效; 4.筛选并规范出血性卒中微创治疗技术,提高治愈率,在全国范围示范推广。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To establish the minimally invasive treatment technique with the monitoring system of the intracranial pressure, the brain temperature, and the biological information by the needle electrode; 2. To establish the CT-guided simulated brain structure and the function orientation and analysing system for the hypertensive intracerebral hemorrhage; 3. To assess and standardize the efficacy of CT-guided stereotactic minimally invasive techniques for evacuation of hematoma; 4. To screening and standardize the minimally invasive treatment technique for the hemorrhagic stroke, with the aim to improve cure rates and then generalize the treatment technique in China. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1、动脉瘤、血管畸形或肿瘤卒中引起的出血; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Hemorrhage resulted from intracranial aneurysm, vascular malformaions or tumor; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2012-01-01 00:00:00至 To 2015-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2012-01-01 00:00:00 至 To 2014-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由李蹊用随机数生成器生随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
random number sequence was generated using random number generator by Xi Li |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
|
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
|
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
|
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
|
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
|
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |